Shoulder Options Receives 510(k) Clearance for Its Proprietary Fracture Plate, the GTFx

Waxhaw, NC, March 14, 2014 --(PR.com)-- Shoulder Options Inc. announced today that it has received FDA clearance for another novel shoulder device, the Greater Tuberosity Fracture Plate (i.e. GTFx).

Developed in collaboration with T. Bradley Edwards, MD, John Costouros, MD and Rhett Hobgood, MD, The patent pending GTFx plate is a minimally invasive method of treatment for fractures of the greater tuberosity and for the treatment of cuff avulsions. The GTFx combines an asymmetrical low profile design with a novel and effective method of suture placement to optimize plate fit and fixation.

“The GTFx is the first device designed specifically for treatment of greater tuberosity fractures of the proximal humerus bone,” said Scott Humphrey, MD and Chief Innovation Officer of the organization, “We are very proud to make it available to surgeons around the country.”

For Jeff Martin, Shoulder Options’ Vice President of Commercial Operations, “Incorporating the unique GTFx plate into our commercialized AFT proximal humeral fracture system will allow surgeons to more effectively and less invasively treat a greater variety of proximal humeral fractures without the need of many different systems.”